申请人:Sankyo Company, Limited
公开号:US05002942A1
公开(公告)日:1991-03-26
Compounds of formula (I): ##STR1## in which: R.sup.1 is aryl or aromatic heterocyclic; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkoxy, halogen, phenyl, phenoxy, C.sub.1 -C.sub.6 alkylthio, phenylthio, C.sub.1 -C.sub.6 haloalkyl, cyano or nitro, or together are alkylene optionally containing oxygen; R.sup.4 is hydrogen, aliphatic acyl, cycloalkylcarbonyl, cycloalkoxycarbonyl, aromatic acyl, alkoxycarbonyl or benzyloxycarbonyl; R.sup.5 and R.sup.6 are alkyl; and X is oxygen, sulfur or methylene, have calcium channel blocking activity and can serve for the treatment or prophylaxis of cardiovascular diseases and disorders. They may be prepared by reacting a corresponding compound where R.sup.4 is hydrogen and the aminoethyl group is replaced by hydrogen with a compound providing the aminoethyl group and the, if required, acylating the product.
式(I)的化合物:##STR1##其中:R.sup.1是芳基或芳香杂环基;R.sup.2和R.sup.3是氢、烷基、烷氧基、卤素、苯基、苯氧基、C.sub.1-C.sub.6烷硫基、苯硫基、C.sub.1-C.sub.6卤代烷基、氰基或硝基,或者一起是含氧的烷基;R.sup.4是氢、脂肪酰基、环烷基羰基、环烷氧羰基、芳香酰基、烷氧羰基或苄氧羰基;R.sup.5和R.sup.6是烷基;X是氧、硫或亚甲基。这些化合物具有钙通道阻滞活性,可用于治疗或预防心血管疾病和紊乱。它们可以通过将R.sup.4为氢且氨乙基基团被氢取代的相应化合物与提供氨乙基基团的化合物反应制备,并在必要时酰化产物。